Evidence map›Paper›PMID 32748413›Full record

ArticleDrug and alcohol review2020

US national treatment admissions with opioids and benzodiazepines.

Cynthia L Arfken, Darlene D Owens, Mark K Greenwald

Open access · greenAbstract read
In one paragraph

Article in Drug and alcohol review, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.5field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Perioperative Management of Patients on Buprenorphine.Current pain and headache reports · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Cynthia L ArfkenDepartment of Psychiatry and Behavioral Neurosciences, School of Medicine, Wayne State University, Detroit, USA.ORCID 0000-0002-8167-6955
Darlene D OwensDetroit Wayne Integrated Health Network, Detroit, USA.
Mark K GreenwaldDepartment of Psychiatry and Behavioral Neurosciences, School of Medicine, Wayne State University, Detroit, USA.
Wayne State University · USEugene Applebaum College of Pharmacy and Health Sciences · US

Funding

Opioid/benzodiazepine polydrug abuse: Integrating research on mechanisms, treatment and policiesR33DA044946 · NIDA · WAYNE STATE UNIVERSITY · PI ARFKEN, CYNTHIA L, GREENWALD, MARK K · 2021 to 2023
$1.9M
Opioid/benzodiazepine polydrug abuse: Integrating research on mechanisms, treatment and policiesR21DA044946 · NIDA · WAYNE STATE UNIVERSITY · PI ARFKEN, CYNTHIA L, GREENWALD, MARK K · 2018 to 2019
$416k
NIDA NIH HHS R21 DA044946NIDA NIH HHS R33 DA044946
6 · The paper itself

Abstract

INTRODUCTION AND

aimsOpioids and benzodiazepines (O/BZD) are increasingly involved in drug overdose deaths in the USA. Expanding treatment capacity may reduce these deaths. Knowledge about co-occurring O/BZD admissions compared to opioid admissions (opioid) is needed to plan this expansion. DESIGN AND

methodsUS treatment admissions to specialty facilities for 2011-2017 were analysed for trends and 2017 for group differences. Due to 1.9 million admissions in 2017, comparisons between O/BZD and opioid admissions were summarised as effect sizes. Additional analysis compared the administratively pre-coded category 'other opiates and synthetics' to other opiates and synthetics/benzodiazepines admissions to control for possible similarity in drug source. Differences within O/BZD admissions by primary drug were explored.

resultsAlthough opioid admissions showed a steady increase over time (25.9% to 38.2%), O/BZD admissions showed increases until decline in 2017 (3.2% to 4.0%). In 2017 no factor reached moderate effect size (≥0.2) in group comparisons or within the O/BZD admissions. Heroin was self-reported in 70% of both O/BZD and opioid admissions. DISCUSSION AND

conclusionsNo meaningful US national differences on data routinely collected were found for O/BZD compared to opioid admissions including the subgroup with other opiates and synthetics only. Efforts to expand existing opioid treatment in specialty treatments may help reduce opioid and O/BZD deaths. However, the analysis could not address whether changes in treatment would improve outcomes.

Indexed as

Analgesics, OpioidBenzodiazepinesDrug OverdoseHospitalizationHumansAnalgesics, OpioidBenzodiazepinesadmissionbenzodiazepineinjectionopioidtreatment

Identifiers

PMID32748413
PMCPMC10336643
OpenAlexW3047109041

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.